系统性红斑狼疮治疗迎利好,诺诚健华、阿斯利康等多药企创新药获新突破

动脉网
Feb 11

全球超340万系统性红斑狼疮(SLE)患者,中国约100万,药物需求迫切。国内药企持续发力,2月10日,杭州尚健生物自主研发的SG301 SC注射液获受理,为国内首个获批临床的皮下注射抗CD38人源化单克隆抗体,早期临床数据显示其安全性和有效性良好;2月9日,诺诚健华自主研发的VAV1分子胶降解剂ICP-538获批开展临床研究,其核心产品奥布替尼用于治疗SLE的三期临床试验也已获批开展。国际药企也...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10